@article{a1d4fda52b3647e0b6fad96e23daef70,
title = "Fatigue in patients with chronic disease: results from the population-based Lifelines Cohort Study",
abstract = "(1) To evaluate the prevalence of severe and chronic fatigue in subjects with and without chronic disease; (2) to assess to which extent multi-morbidity contributes to severe and chronic fatigue; and (3) to identify predisposing and associated factors for severe and chronic fatigue and whether these are disease-specific, trans-diagnostic, or generic. The Dutch Lifelines cohort was used, including 78,363 subjects with (n = 31,039, 53 +/- 12 years, 33% male) and without (n = 47,324, 48 +/- 12 years, 46% male) >= 1 of 23 chronic diseases. Fatigue was assessed with the Checklist Individual Strength-Fatigue. Compared to participants without a chronic disease, a higher proportion of participants with >= 1 chronic disease were severely (23% versus 15%, p < 0.001) and chronically (17% versus 10%, p < 0.001) fatigued. The odds of having severe fatigue (OR [95% CI]) increased from 1.6 [1.5-1.7] with one chronic disease to 5.5 [4.5-6.7] with four chronic diseases; for chronic fatigue from 1.5 [1.5-1.6] to 4.9 [3.9-6.1]. Multiple trans-diagnostic predisposing and associated factors of fatigue were found, explaining 26% of variance in fatigue in chronic disease. Severe and chronic fatigue are highly prevalent in chronic diseases. Multi-morbidity increases the odds of having severe and chronic fatigue. Several trans-diagnostic factors were associated with fatigue, providing a rationale for a trans-diagnostic approach.",
keywords = "OBSTRUCTIVE PULMONARY-DISEASE, SYSTEMIC-LUPUS-ERYTHEMATOSUS, STAGE RENAL-DISEASE, MULTIPLE-SCLEROSIS, EXERCISE INTERVENTIONS, RHEUMATOID-ARTHRITIS, DEPRESSION, PEOPLE, SYMPTOMS, QUESTIONNAIRE",
author = "Y.M.J. Goertz and A.M.J. Braamse and M.A. Spruit and D.J.A. Janssen and Z. Ebadi and {Van Herck}, M. and C. Burtin and J.B. Peters and M.A.G. Sprangers and F. Lamers and J.W.R. Twisk and M.S.Y. Thong and J.H. Vercoulen and S.E. Geerlings and A.W. Vaes and R.J.H.C.G. Beijers and {van Beers}, M. and A.M.W.J. Schols and J.G.M. Rosmalen and H. Knoop",
note = "Funding Information: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf. Y.M.J.G., A.M.J.B., Z.E., M.V.H., C.B., J.B.P., M.A.G.S., F.L., J.W.R.T., M.S.Y.T., J.H.V., S.E.G., A.W.V., R.J.H.C.G.B., M.B., A.M.W.J.S., J.G.M.R. and H.K. have nothing to disclose. D.A.J. reports personal fees from Novartis, personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, outside the submitted work. M.A.S. reports grants from Lung Foundation Netherlands, grants from Stichting Astma Bestrijding, grants and personal fees from Boehringer Ingelheim, and grants and personal fees from AstraZeneca, outside the submitted work. Funding Information: The Lifelines Biobank initiative has been made possible by subsidy from the Dutch Ministry of Health, Welfare and Sport, the Dutch Ministry of Economic Affairs, the University Medical Center Groningen (UMCG the Netherlands), University Groningen and the Northern Provinces of the Netherlands. Y.M.J.G. is financially supported by Lung Foundation Netherlands grant 4.1.16.085. The funding organizations had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. Publisher Copyright: {\textcopyright} 2021, The Author(s).",
year = "2021",
month = oct,
day = "25",
doi = "10.1038/s41598-021-00337-z",
language = "English",
volume = "11",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",
}